Skip to content

Clinical observation of shuitong and Shuijin points to inhibit sufentanil-induced cough

Clinical observation of shuitong and Shuijin points to inhibit sufentanil-induced cough

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049406
Enrollment
Unknown
Registered
2021-08-02
Start date
2021-08-01
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complications from sufentanil

Interventions

Experimental group:acupuncture at shuitong point and Shuijin point before induction of anesthesia
Control group:2ml normal saline was injected intravenously before induction of anesthesia

Sponsors

Rizhao Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Normal heart and lung function; 2. No history of drug use or long-term use of opioids; 3. Tolerate surgical anesthesia.

Exclusion criteria

Exclusion criteria: 1. Preoperative body temperature >38.5 degree; 2. History of upper respiratory tract infection in the past 2 weeks before surgery; 3. Chronic obstructive pulmonary disease, history of asthma; 4. Thoracic surgery, history of hypertension, smoking, use of hormones, bronchodilators, vascular converting enzyme inhibitors.

Design outcomes

Primary

MeasureTime frame
Choking cough cases;Severity of coughing;

Secondary

MeasureTime frame
Changes in hemodynamics;Number of chest wall stiffness cases;

Countries

China

Contacts

Public ContactXu Jiping

Rizhao Central Hospital

rzhwfxjp@163.com+86 13792045179

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026